abstract
With antiretroviral therapy, patients who are human immunodeficiency virus (HIV)-positive are increasingly becoming candidates for total hip arthroplasty (THA) and total knee arthroplasty (TKA). Prior reports focus on perioperative complications, but longer-term outcomes remain unclear. The authors specifically analyzed clinical outcomes, perioperative complications, and survivorship free of periprosthetic joint infection (PJI) of THAs and TKAs in HIV-positive patients who had extended follow-up. A total of 21 HIV-positive patients who underwent 29 primary arthroplasties (14 THAs, 15 TKAs) from 1992 to 2012 were retrospectively reviewed. Mean age was 43 years and mean follow-up was 8 years. Mean perioperative CD4 cell count was 450 cells/mL; only 2 patients had perioperative CD4 cell counts less than 200 cells/mL. At mid-term follow-up, THAs and TKAs were reliable in improving function (mean postoperative Harris Hip Score: 87, P<.01; mean postoperative Knee Society Score: 83, P<.01). The rate of perioperative complications was high (17%). Patients with both hemophilia and HIV were at particular risk for complications at 33% (P=.04). Survivorship free of deep PJI was 100% in THAs at 10 years and 93% in TKAs at 10 years. Only 1 (7%) patient (1 TKA), who had a perioperative CD4 cell count of less than 200 cells/ mL, was revised for deep PJI. In HIV-positive patients, both THAs and TKAs are reliable in alleviating pain and improving clinical function at mid-term follow-up. However, HIV-positive patients are at substantial risk of perioperative complications, especially with comorbid hemophilia. With antiretroviral therapy and maintained CD4 cell counts above 200 cells/mL, survivorship free of deep PJI approaches 100%. [Orthopedics. 2017; 40(4):e699-e702.] cation regimens, interest has increased in the clinical outcomes and complications of HIV-positive patients undergoing elective total hip arthroplasty (THA) and total knee arthroplasty (TKA). [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Reliable pain and functional improvement with higher rates of complications and less durability of total joint arthroplasty (TJA) for the treatment of hemophilic arthropathy have been well documented. [5] [6] [7] However, the current literature on the clinical outcomes and the complication and revision rates of TJA in HIV-positive patients is conflicting. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Some studies showed a high rate of early failure and an increased rate of deep periprosthetic joint infections (PJI), 11, [13] [14] [15] [16] [17] especially in patients with low CD4 counts and comorbid hemophilia and intravenous drug use, 13, 14 whereas other reports showed similar outcomes to the general population. [8] [9] [10] [11] Furthermore, few studies evaluate the long-term outcomes in this patient population.
The primary aim of the current study was to evaluate the immediate and midterm clinical outcomes, complications, survivorship free of deep PJI, and survivorship free of revision and reoperation of TKAs and THAs in HIV-positive patients.
Materials and Methods
Through the use of the authors' total joint registry, all HIV-positive patients undergoing primary THA or TKA at a single, tertiary care academic center between 1992 and 2012 were identified. Institutional review board approval was obtained prior to study initiation.
Clinical function was analyzed by measuring patients' Harris Hip Score (HHS) 18 and Knee Society Score (KSS). 19 Revision, reoperation, and complication rates were determined using the medical records.
Twenty-one HIV-positive patients who underwent 14 THAs and 15 TKAs during the study period were identified. Mean age was 43 years (range, 28-64 years) at the time of arthroplasty. One (5%) patient was a woman. Mean body mass index was 26 kg/m 2 (range, 17-48 kg/m 2 ). Fifteen (53%) of the 29 arthroplasties occurred in patients with both HIV and hemophilia. Mean perioperative CD4 count was 450 cells/mL (range, 91-1465 cells/mL). Only 2 patients (1 THA, 1 TKA) had perioperative CD4 counts less than 200 cells/mL. All patients were taking perioperative HAART. Mean clinical follow-up was 8 years (range, 2-21 years). One patient died of cancer at 1 year postoperatively.
Statistical Methods
All continuous variables were analyzed using Student's t tests. KaplanMeier survivorship curves were constructed as survivorship free of deep PJI and survivorship free of any revision or reoperation. Ninety-five percent confidence intervals (95% CIs) were calculated for each survivorship analysis. Subgroup analysis was performed to identify specific risk factors for complications. Statistics were analyzed using JMP version 10.0 software (SAS, Cary, North Carolina). A significance value was set at an α less than 0.05.
results

Clinical Outcomes
At mid-term follow-up, both THA and TKA were reliable in alleviating pain and improving function in patients with HIV. Mean HHS improved from 48 preoperatively to 87 postoperatively (P<.01). Similarly, mean KSS improved from 47 preoperatively to 83 postoperatively (P<.01).
Complications
The overall perioperative complication rate was 17%. Comorbid hemophilia was a significant risk factor for complications, with a rate of 33% compared with no complications in the nonhemophiliac group (P=.04) (Table) . Two (7%) patients experienced postoperative bleeding and hematomas acutely postoperative, requiring additional coagulant factors and 1 hospital re-admission. One (3.5%) patient developed arthrofibrosis with knee flexion less than 60° that required manipulation, and 2 (7%) patients developed flexion contractures greater than 10°. No significant difference in clinical outcomes (ie, HHS or KSS), revisions, or reoperations was observed between hemophiliacs and nonhemophiliacs (Table) .
Survivorship
One (7%) knee was revised for a deep periprosthetic infection at 1 month postoperatively in a patient with a CD4 count less than 200 cells/mL perioperatively. The patient underwent 8 procedures that eventually resulted in an arthrodesis. No other revisions or reoperations for infection occurred. Thus, survivorship free of deep PJI was 100% at both 5 and 10 years for THAs and 93% (95% CI, 81%-100%) at both 5 and 10 years for TKAs (Figure 1) . Three (21%) hips required revision at a mean of 3 years after the index arthroplasty. Two (14%) hips were revised for adverse local tissue reactions to metal-on-metal constructs. The other hip (n=1, 7%) was revised for recurrent instability. One (7%) additional reoperation occurred. One (7%) additional reoperation occurred for a patient who underwent open reduction and internal fixation of a Vancouver B 1 periprosthetic femur fracture. No other septic or aseptic reoperations or revisions occurred in either THAs or TKAs. As such, 5-and 10-year survivorship free of any revision or reoperation was 72% (95% CI, 46%-98%) and 62%, respectively, for THAs (Figure 2) . Survivorship free of any revision or reoperation was 93% (95% CI, 81%-100%) at both 5 and 10 years for TKAs (Figure 2) .
discussion
With the introduction of HAART, the life expectancy for HIV-positive patients has drastically increased.
1,2 Patients with HIV are at an increased risk for avascular necrosis of the hip and knee for multiple underlying reasons and are increasingly candidates for TJA. 4 With the high rate of comorbidities (including intravenous drug use and hemophilia), intense medication regimens, and immunodeficiency, there is an increased concern about poor outcomes of TJA in HIV-positive patients. The current study indicates that HIVpositive patients have reliable improvement in pain and clinical function after lower extremity total joint arthroplasty but a markedly increased rate of perioperative complications with poorer survivorship, particularly those patients with concomitant hemophilia.
At mid-term follow-up, clinical outcomes in the form of HHS and KSS remained significantly improved compared with preoperative levels. The literature on the risk of revision and perioperative complications in HIV-positive patients undergoing TJA is mixed.
Graham et al 8 reported no revisions or perioperative complications in 43 THRs at a mean follow-up of 3.5 years. However, none of these patients had hemophilia. The current authors similarly found no increased risk of perioperative complications in HIV-positive patients without hemophilia. However, HIV-positive patients with comorbid hemophilia did have a significantly higher rate (33%) of perioperative complications. The increased rate of perioperative complications in patients with hemophilia has been well documented in the literature. [5] [6] [7] In a previous study from the authors' institution, Parvizi et al 15 reported that 6 (29%) of 21 total joints developed a deep periprosthetic infections in HIV-positive patients at a mean of 10 years of followup. However, all of those patients had poor CD4 counts and died of AIDS-related complications. Ragni et al 13 similarly showed that HIV-positive hemophiliacs with CD4 count less than 200 cells/mL have a 30% rate of deep periprosthetic infection after TKA and 14% after THA. Lin et al 11 reported an increased rate of deep periprosthetic infections at 9% in HIV-positive patients compared with 2% in HIV-negative patients, but most of the patients in this cohort were former intravenous drug users or had significant liver disease.
In the current study, no patients with CD4 count greater than 200 cells/mL and on HAART had an early or late infection at a mean follow-up of 8 years. One of 2 patients with perioperative CD4 counts less than 200 cells/mL developed a deep PJI. This is consistent with previous reports and current literature that patients with AIDS are at a higher risk of early and late deep periprosthetic infections. 11, 15 However, with optimal medical management and careful patient selection, HIVpositive patients taking HAART and with adequate CD4 counts do not have a significantly higher risk of early or late deep infection.
However, there was also a high rate of early revision and reoperation in HIVpositive patients who underwent THA in the current series, with a 5-year survivorship free of revision or reoperation of 72%. All of the early revisions were secondary to mechanical or implant-specific complications, including adverse local tissue reactions from metal-on-metal articulations in 2 patients, as well as recurrent instability in 1 patient. This lower than expected survivorship is likely secondary to a sampling error and the relatively small patient cohort rather than attributable to the patients' underlying HIV status. Although the numbers in this study are low, it is unclear whether HIV status independently affected the risk of revision in these cases.
The main limitation of the current study is the relatively small number of patients. Trends and risk factors for revision, infection, and poor outcomes are difficult to analyze with small patient numbers. However, this is one of the larger patient series in the literature with extended follow-up to analyze HIV-positive patients undergoing TJA. Moreover, although national database studies have been published, 9,11 they focus on in-hospital complications, not long-term outcomes. Furthermore, half of the patients in the current series had comorbid hemophilia, which may confound the results; given the nature of disease transmission, HIVpositive patients often have comorbid conditions that are potential confounders. However, the current authors performed a subgroup analysis to better analyze risk factors for complications, revisions, and infection.
conclusion
With optimal perioperative and continued medical management to ensure adequate CD4 counts and immunocompetency, HIV-positive patients have reliable pain relief and improved clinical function with TJA. Although the rate of deep periprosthetic infection has improved with contemporary practice, HIV-positive patients undergoing TJA still have a markedly increased complication rate with a poorer survivorship, primarily those patients with comorbid hemophilia.
references
